# RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

> **NCT06243458** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **GCP-Service International West GmbH** · enrollment: 41 (actual)

## Conditions studied

- Low Risk Myelodysplastic Syndromes

## Interventions

- **DRUG:** RVU120 (SEL120)

## Key facts

- **NCT ID:** NCT06243458
- **Lead sponsor:** GCP-Service International West GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-10
- **Primary completion:** 2026-05
- **Final completion:** 2027-05
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-05-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06243458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06243458, "RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06243458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*